Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay.

Longosz AF, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS. 2014 May 15;28(8):1227-32. doi: 10.1097/QAD.0000000000000221.

2.

Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.

Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, Mueller AC, Jacobson LP, Margolick JB, Brown J, Rinaldo CR, Quinn TC, Eshleman SH; Multicenter Aids Cohort Study Macs.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):816-22. doi: 10.1089/AID.2011.0258. Epub 2011 Dec 1.

3.

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Justman JE, Hodder SL, Quinn TC, Eshleman SH, Laeyendecker O.

PLoS One. 2013 Dec 27;8(12):e82772. doi: 10.1371/journal.pone.0082772. eCollection 2013.

4.

Short Communication: Low False Recent Rate of Limiting-Antigen Avidity Assay Among Long-Term Infected Subjects from Guangxi, China.

Yu L, Laeyendecker O, Wendel SK, Liang F, Liu W, Wang X, Wang L, Pang X, Fang Z.

AIDS Res Hum Retroviruses. 2015 Dec;31(12):1247-9. doi: 10.1089/aid.2015.0097. Epub 2015 Sep 2.

5.

Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.

Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS Res Hum Retroviruses. 2014 Apr;30(4):339-44. doi: 10.1089/AID.2013.0169. Epub 2013 Oct 25.

6.

Identifying Risk Factors for Recent HIV Infection in Kenya Using a Recent Infection Testing Algorithm: Results from a Nationally Representative Population-Based Survey.

Kim AA, Parekh BS, Umuro M, Galgalo T, Bunnell R, Makokha E, Dobbs T, Murithi P, Muraguri N, De Cock KM, Mermin J; 2007 KAIS study group.

PLoS One. 2016 May 19;11(5):e0155498. doi: 10.1371/journal.pone.0155498. eCollection 2016.

7.

Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.

Laeyendecker O, Brookmeyer R, Mullis CE, Donnell D, Lingappa J, Celum C, Baeten JM, Campbell MS, Essex M, de Bruyn G, Farquhar C, Quinn TC, Eshleman SH; Partners in Prevention HSV/HIV Transmission Study Team.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1177-83.

8.

Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.

Duong YT, Qiu M, De AK, Jackson K, Dobbs T, Kim AA, Nkengasong JN, Parekh BS.

PLoS One. 2012;7(3):e33328. doi: 10.1371/journal.pone.0033328. Epub 2012 Mar 27.

9.

Performance of Bio-Rad and Limiting Antigen Avidity Assays in Detecting Recent HIV Infections Using the Quebec Primary HIV-1 Infection Cohort.

Serhir B, Hamel D, Doualla-Bell F, Routy JP, Beaulac SN, Legault M, Fauvel M, Tremblay C; Quebec Primary HIV infection study group.

PLoS One. 2016 May 25;11(5):e0156023. doi: 10.1371/journal.pone.0156023. eCollection 2016.

10.

Cascade of HIV care and population viral suppression in a high-burden region of Kenya.

Maman D, Zeh C, Mukui I, Kirubi B, Masson S, Opolo V, Szumilin E, Riche B, Etard JF.

AIDS. 2015 Jul 31;29(12):1557-65. doi: 10.1097/QAD.0000000000000741.

11.

HIV infection and incidence of ischemic stroke.

Marcus JL, Leyden WA, Chao CR, Chow FC, Horberg MA, Hurley LB, Klein DB, Quesenberry CP Jr, Towner WJ, Silverberg MJ.

AIDS. 2014 Aug 24;28(13):1911-9. doi: 10.1097/QAD.0000000000000352.

PMID:
24937309
12.

Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.

Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O.

PLoS One. 2013;8(2):e55525. doi: 10.1371/journal.pone.0055525. Epub 2013 Feb 20.

13.

HIV incidence determination in the United States: a multiassay approach.

Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Mehta SH, Astemborski J, Jacobson LP, Margolick JB, Brown J, Quinn TC, Eshleman SH.

J Infect Dis. 2013 Jan 15;207(2):232-9. doi: 10.1093/infdis/jis659. Epub 2012 Nov 5.

14.

No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.

Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N, Gerstoft J.

HIV Med. 2013 Jul;14(6):362-9. doi: 10.1111/hiv.12016. Epub 2013 Feb 21.

15.

Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.

Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, Salata RA, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS Res Hum Retroviruses. 2015 Apr;31(4):421-7. doi: 10.1089/AID.2014.0081. Epub 2014 Nov 19.

16.

Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.

Nash D, Wu Y, Elul B, Hoos D, El Sadr W; International Center for AIDS Care and Treatment Programs.

AIDS. 2011 Jul 31;25(12):1523-33. doi: 10.1097/QAD.0b013e32834811b2.

17.

Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.

Wendel SK, Longosz AF, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Quinn TC, Laeyendecker O.

AIDS Res Hum Retroviruses. 2017 Apr;33(4):325-327. doi: 10.1089/AID.2016.0105. Epub 2017 Jan 11.

PMID:
27875908
18.

Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.

Longosz AF, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):390-6. doi: 10.1097/QAI.0000000000000006.

19.

Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.

Kirkpatrick AR, Patel EU, Celum CL, Moore RD, Blankson JN, Mehta SH, Kirk GD, Margolick JB, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS Res Hum Retroviruses. 2016 Aug;32(8):756-62. doi: 10.1089/AID.2015.0198. Epub 2016 May 5.

PMID:
26988426
20.

Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.

Hauser A, Santos-Hoevener C, Meixenberger K, Zimmermann R, Somogyi S, Fiedler S, Hofmann A, Bartmeyer B, Jansen K, Hamouda O, Bannert N, Kuecherer C.

PLoS One. 2014 Jun 3;9(6):e98038. doi: 10.1371/journal.pone.0098038. eCollection 2014.

Supplemental Content

Support Center